{"symbol": "JNJ", "publishedDate": "2024-04-02 09:01:05", "publisher": "Zacks Investment Research", "title": "AI ETFs: Q1 of 2024 Update", "image": "https://images.financialmodelingprep.com/news/ai-etfs-q1-of-2024-update-20240402.jpg", "site": "zacks.com", "text": "The year 2023 was crucial in the Artificial Intelligence (AI) industry. So far this year, we have seen Apple's efforts to join the AI race more prudently, Amazon's billion dollar investment in AI start-up and Nvidia's efforts to foray into various industries with AI initiatives.", "url": "https://www.zacks.com/stock/news/2248900/ai-etfs-q1-of-2024-update?cid=CS-STOCKNEWSAPI-FT-etf_news_and_commentary-2248900", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-02T09:01:05-04:00", "date_et": "2024-04-02"}
{"symbol": "JNJ", "publishedDate": "2024-04-02 13:40:46", "publisher": "Seeking Alpha", "title": "12 Dividend Increases Expected In April 2024", "image": "https://images.financialmodelingprep.com/news/12-dividend-increases-expected-in-april-2024-20240402.jpg", "site": "seekingalpha.com", "text": "12 expected dividend increases in April 2024. Dividend growth is crucial for reaching financial freedom and combating high inflation.", "url": "https://seekingalpha.com/article/4681783-12-dividend-increases-expected-april-2024", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-02T13:40:46-04:00", "date_et": "2024-04-02"}
{"symbol": "JNJ", "publishedDate": "2024-04-02 16:30:00", "publisher": "Business Wire", "title": "Johnson & Johnson to Participate in the BofA Securities Health Care Conference", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-to-participate-in-the-bofa-securities-health-20240402.jpg", "site": "businesswire.com", "text": "NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the BofA Securities Health Care Conference on Tuesday, May 14th, at the Encore Hotel, Las Vegas, Nevada. John Reed, Executive Vice President, Innovative Medicine, R&D, will represent the Company in a session scheduled at 4:40 pm (Eastern Time). This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com. Th.", "url": "https://www.businesswire.com/news/home/20240402572248/en/Johnson-Johnson-to-Participate-in-the-BofA-Securities-Health-Care-Conference/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-02T16:30:00-04:00", "date_et": "2024-04-02"}
{"symbol": "JNJ", "publishedDate": "2024-04-03 09:56:13", "publisher": "Zacks Investment Research", "title": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar", "image": "https://images.financialmodelingprep.com/news/these-2-medical-stocks-could-beat-earnings-why-they-should-be-20240403.jpg", "site": "zacks.com", "text": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.", "url": "https://www.zacks.com/stock/news/2249582/these-2-medical-stocks-could-beat-earnings-why-they-should-be-on-your-radar?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|zacks_education_earnings_esp-2249582", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-03T09:56:13-04:00", "date_et": "2024-04-03"}
{"symbol": "JNJ", "publishedDate": "2024-04-03 13:16:21", "publisher": "Zacks Investment Research", "title": "Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?", "image": "https://images.financialmodelingprep.com/news/will-johnson-johnson-jnj-beat-estimates-again-in-its-20240403.jpg", "site": "zacks.com", "text": "Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.", "url": "https://www.zacks.com/stock/news/2249996/will-johnson-johnson-jnj-beat-estimates-again-in-its-next-earnings-report?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_7-2249996", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-03T13:16:21-04:00", "date_et": "2024-04-03"}
{"symbol": "JNJ", "publishedDate": "2024-04-03 20:48:00", "publisher": "InvestorPlace", "title": "Rich Returns at a Discount: 3 Dividend Aristocrats Trading at 52-Week Lows", "image": "https://images.financialmodelingprep.com/news/rich-returns-at-a-discount-3-dividend-aristocrats-trading-20240403.jpg", "site": "investorplace.com", "text": "Looking for Dividend aristocrats trading at their 52-week lows? If so, you've come to the right place.", "url": "https://investorplace.com/2024/04/rich-returns-at-a-discount-3-dividend-aristocrats-trading-at-52-week-lows/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-03T20:48:00-04:00", "date_et": "2024-04-03"}
{"symbol": "JNJ", "publishedDate": "2024-04-04 08:01:07", "publisher": "Zacks Investment Research", "title": "Time to Tap Healthcare ETFs on Nvidia's AI Ambition?", "image": "https://images.financialmodelingprep.com/news/time-to-tap-healthcare-etfs-on-nvidias-ai-ambition-20240404.jpg", "site": "zacks.com", "text": "At Nvidia's last week's GTC AI conference, the company announced partnerships in the healthcare sector, representing a strategic move toward expanding its revenue streams beyond tech sectors.", "url": "https://www.zacks.com/stock/news/2250231/time-to-tap-healthcare-etfs-on-nvidia-s-ai-ambition?cid=CS-STOCKNEWSAPI-FT-etf_news_and_commentary-2250231", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-04T08:01:07-04:00", "date_et": "2024-04-04"}
{"symbol": "JNJ", "publishedDate": "2024-04-04 18:01:00", "publisher": "Business Wire", "title": "Johnson & Johnson Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment Corporation", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-recommends-shareholders-reject-minitender-offer-by-trc-20240404.jpg", "site": "businesswire.com", "text": "NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation of Ontario, Canada to purchase up to 1 million shares of Johnson & Johnson common stock at a price of $151.23 per share in cash. TRC Capital Investment's offer price of $151.23 per share is approximately 4.12% lower than the $157.73 closing share price of Johnson & Johnson's common stock on April 2,.", "url": "https://www.businesswire.com/news/home/20240404244958/en/Johnson-Johnson-Recommends-Shareholders-Reject-%E2%80%9CMini-Tender%E2%80%9D-Offer-by-TRC-Capital-Investment-Corporation/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-04T18:01:00-04:00", "date_et": "2024-04-04"}
{"symbol": "JNJ", "publishedDate": "2024-04-05 06:31:00", "publisher": "Business Wire", "title": "Johnson & Johnson to Acquire Shockwave Medical", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-to-acquire-shockwave-medical-20240405.jpg", "site": "businesswire.com", "text": "NEW BRUNSWICK, N.J. & SANTA CLARA, Calif.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) and Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave”) today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 per share in cash, corresponding to an enterprise value of approximately $13.1 billion including cash acquired. The transaction was approved by both companies' boards of directors. The a.", "url": "https://www.businesswire.com/news/home/20240405052557/en/Johnson-Johnson-to-Acquire-Shockwave-Medical/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-05T06:31:00-04:00", "date_et": "2024-04-05"}
{"symbol": "JNJ", "publishedDate": "2024-04-05 06:39:15", "publisher": "Reuters", "title": "Johnson & Johnson to buy Shockwave Medical for $12.5 bln", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-to-buy-shockwave-medical-for-125-bln-20240405.jpg", "site": "reuters.com", "text": "Johnson & Johnson will buy medical device maker Shockwave Medical for about $12.5 billion, the companies said on Friday, helping the healthcare conglomerate boost its portfolio of medical devices.", "url": "https://www.reuters.com/markets/deals/johnson-johnson-buy-shockwave-medical-125-bln-deal-2024-04-05/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-05T06:39:15-04:00", "date_et": "2024-04-05"}
{"symbol": "JNJ", "publishedDate": "2024-04-05 06:40:00", "publisher": "Market Watch", "title": "Johnson & Johnson to acquire Shockwave Medical in $13.1 billion deal", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-to-acquire-shockwave-medical-in-131-billion-20240405.jpg", "site": "marketwatch.com", "text": "Johnson & Johnson JNJ, -1.14% has agreed to acquire Shockwave Medical Inc. SWAV, -0.23% in an all-cash deal with an enterprise value of about $13 billion, the companies said Friday. J&J will pay $335 a share in cash, equal to a 4.7% premium over Shockwave's closing price Thursday at $319.99.", "url": "https://www.marketwatch.com/story/johnson-johnson-to-acquire-shockwave-medical-in-13-1-billion-deal-c9e71017", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-05T06:40:00-04:00", "date_et": "2024-04-05"}
{"symbol": "JNJ", "publishedDate": "2024-04-05 07:12:00", "publisher": "Barrons", "title": "Johnson & Johnson to Buy Shockwave Medical. It's a Cardio Health Play.", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-to-buy-shockwave-medical-its-a-cardio-20240405.jpg", "site": "barrons.com", "text": "Johnson & Johnson is buying the medical-devices maker for a total enterprise value of about $13.1 billion.", "url": "https://www.barrons.com/articles/johnson-johnson-jnj-stock-shockwave-medical-de83a930", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-05T07:12:00-04:00", "date_et": "2024-04-05"}
{"symbol": "JNJ", "publishedDate": "2024-04-05 07:18:49", "publisher": "Invezz", "title": "Johnson & Johnson to buy Shockwave Medical for $12.5 billion", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-to-buy-shockwave-medical-for-125-billion-20240405.jpg", "site": "invezz.com", "text": "Shockwave Medical Inc (NASDAQ: SWAV) is in the green today after Johnson & Johnson (NYSE: JNJ) said it will buy the medical device maker for $12.5 billion. Shockwave Medical stock priced at a premium The all-cash agreement values each share of Shockwave Medical at $335 – a 5.0% premium on their previous close.", "url": "https://invezz.com/news/2024/04/05/johnson-and-johnson-to-buy-shockwave-medical/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-05T07:18:49-04:00", "date_et": "2024-04-05"}
{"symbol": "JNJ", "publishedDate": "2024-04-05 07:18:49", "publisher": "Invezz", "title": "Johnson & Johnson to buy Shockwave Medical for $12.5 billion", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-to-buy-shockwave-medical-for-125-billion-20240405.jpg", "site": "invezz.com", "text": "Shockwave Medical Inc (NASDAQ: SWAV) is in the green today after Johnson & Johnson (NYSE: JNJ) said it will buy the medical device maker for $12.5 billion. Shockwave Medical stock priced at a premium The all-cash agreement values each share of Shockwave Medical at $335 – a 5.0% premium on their previous close.", "url": "https://invezz.com/news/2024/04/05/johnson-and-johnson-to-buy-shockwave-medical/?utm_source=snapi", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-05T07:18:49-04:00", "date_et": "2024-04-05"}
{"symbol": "JNJ", "publishedDate": "2024-04-05 08:10:23", "publisher": "Investors Business Daily", "title": "Johnson & Johnson To Buy Shockwave Medical For $13.1 Billion", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-to-buy-shockwave-medical-for-131-billion-20240405.jpg", "site": "investors.com", "text": "Johnson & Johnson will pay $13.1 billion, or $335 a share, for Shockwave Medical, which has soared in 2024 in part on takeover speculation.", "url": "https://www.investors.com/news/technology/johnson-johnson-to-buy-shockwave-medical-13-1-billion/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-05T08:10:23-04:00", "date_et": "2024-04-05"}
{"symbol": "JNJ", "publishedDate": "2024-04-05 09:31:18", "publisher": "InvestorPlace", "title": "SWAV Stock Alert: Shockwave Medical Lands Big Buyer in Johnson & Johnson", "image": "https://images.financialmodelingprep.com/news/swav-stock-alert-shockwave-medical-lands-big-buyer-in-20240405.png", "site": "investorplace.com", "text": "Johnson & Johnson (NYSE: JNJ ) is buying medical device company Shockwave Medical (NASDAQ: SWAV ) for $13.1 billion. Shockwave makes devices that perform Intravascular Lithotripsy.", "url": "https://investorplace.com/2024/04/swav-stock-alert-shockwave-medical-lands-big-buyer-in-johnson-johnson/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-05T09:31:18-04:00", "date_et": "2024-04-05"}
{"symbol": "JNJ", "publishedDate": "2024-04-05 10:01:45", "publisher": "Forbes", "title": "Johnson & Johnson Buys Shockwave For $13.1 Billion In Latest Cardio Deal", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-buys-shockwave-for-131-billion-in-latest-20240405.jpg", "site": "forbes.com", "text": "Johnson & Johnson will acquire Shockwave Medical in a deal valued at $13.1 billion, according to a joint statement Friday, the latest acquisition by the pharmaceutical firm over the last two years as it expands on cardiovascular intervention.", "url": "https://www.forbes.com/sites/tylerroush/2024/04/05/johnson--johnson-buys-shockwave-for-131-billion-in-latest-cardio-deal/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-05T10:01:45-04:00", "date_et": "2024-04-05"}
{"symbol": "JNJ", "publishedDate": "2024-04-05 10:33:00", "publisher": "WSJ", "title": "Johnson & Johnson to Buy Shockwave Medical in $13.1 Billion Deal", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-to-buy-shockwave-medical-in-131-billion-20240405.jpg", "site": "wsj.com", "text": "The healthcare giant said the addition of the medical-device maker would expand its MedTech cardiovascular portfolio.", "url": "https://www.wsj.com/articles/johnson-johnson-to-buy-shockwave-medical-in-13-1-billion-deal-5c3a45ce", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-05T10:33:00-04:00", "date_et": "2024-04-05"}
{"symbol": "JNJ", "publishedDate": "2024-04-05 11:05:46", "publisher": "Schaeffers Research", "title": "Shockwave Medical Stock Rises After Johnson & Johnson Buyout", "image": "https://images.financialmodelingprep.com/news/shockwave-medical-stock-rises-after-johnson-johnson-buyout-20240405.jpg", "site": "schaeffersresearch.com", "text": "Shockwave Medical Inc (NASDAQ:SWAV) is in the spotlight today, after blue-chip pharmaceutical giant Johnson & Johnson (JNJ) announced it would buy the company for $12.5 billion, boosting its portfolio of cardiovascular disease treatment devices.", "url": "https://www.schaeffersresearch.com/content/news/2024/04/05/shockwave-medical-stock-rises-after-johnson-johnson-buyout", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-05T11:05:46-04:00", "date_et": "2024-04-05"}
{"symbol": "JNJ", "publishedDate": "2024-04-05 11:12:50", "publisher": "Proactive Investors", "title": "Johnson & Johnson to acquire medical device company Shockwave Medical for $13.1B", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-to-acquire-medical-device-company-shockwave-medical-20240405.jpg", "site": "proactiveinvestors.com", "text": "Johnson & Johnson (NYSE:JNJ) (J&J) will bolster its portfolio of medical devices targeting heart disease with its $13.1 billion acquisition of Shockwave Medical. The companies announced on Friday that J&J will acquire Shockwave for $335 per share in cash funded through a combination of cash on hand and debt.", "url": "https://www.proactiveinvestors.com/companies/news/1044688", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-05T11:12:50-04:00", "date_et": "2024-04-05"}
{"symbol": "JNJ", "publishedDate": "2024-04-05 11:12:50", "publisher": "Proactive Investors", "title": "Johnson & Johnson to acquire medical device company Shockwave Medical for $13.1B", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-to-acquire-medical-device-company-shockwave-medical-for-20240405.jpg", "site": "proactiveinvestors.com", "text": "Johnson & Johnson (NYSE:JNJ) (J&J) will bolster its portfolio of medical devices targeting heart disease with its $13.1 billion acquisition of Shockwave Medical. The companies announced on Friday that J&J will acquire Shockwave for $335 per share in cash funded through a combination of cash on hand and debt.", "url": "https://www.proactiveinvestors.com/companies/news/1044688?SNAPI", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-05T11:12:50-04:00", "date_et": "2024-04-05"}
{"symbol": "JNJ", "publishedDate": "2024-04-05 12:25:55", "publisher": "Investopedia", "title": "J&J Acquires Shockwave Medical to Boost Its Cardiovascular Treatment Portfolio", "image": "https://images.financialmodelingprep.com/news/jj-acquires-shockwave-medical-to-boost-its-cardiovascular-treatment-20240405.jpg", "site": "investopedia.com", "text": "Johnson & Johnson (JNJ) announced Friday it was buying Shockwave Medical (SWAV) for $13.1 billion in cash, pushing shares of the maker of cardiovascular catheters to near all-time highs.", "url": "https://www.investopedia.com/jnj-buys-shockwave-medical-for-usd13b-8625313", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-05T12:25:55-04:00", "date_et": "2024-04-05"}
{"symbol": "JNJ", "publishedDate": "2024-04-05 14:55:00", "publisher": "PRNewsWire", "title": "ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Shockwave Medical, Inc.", "image": "https://images.financialmodelingprep.com/news/alert-rowley-law-pllc-is-investigating-proposed-acquisition-of-20240405.jpg", "site": "prnewswire.com", "text": "NEW YORK, April 5, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Shockwave Medical, Inc. (NASDAQ: SWAV) and its board of directors concerning the proposed acquisition of the company by Johnson & Johnson (NYSE: JNJ). Stockholders will receive $335.00 for each share of Shockwave Medical stock that they hold.", "url": "https://www.prnewswire.com/news-releases/alert-rowley-law-pllc-is-investigating-proposed-acquisition-of-shockwave-medical-inc-302109460.html", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-05T14:55:00-04:00", "date_et": "2024-04-05"}
{"symbol": "JNJ", "publishedDate": "2024-04-05 16:31:04", "publisher": "Zacks Investment Research", "title": "Acquisition Watch: Time to Buy Johnson & Johnson (JNJ) or ShockWave Medical's (SWAV) Stock?", "image": "https://images.financialmodelingprep.com/news/acquisition-watch-time-to-buy-johnson-johnson-jnj-or-20240405.jpg", "site": "zacks.com", "text": "News of healthcare behemoth Johnson & Johnson (JNJ) acquiring medical device company ShockWave Medical (SWAV) for $13.1 billion made headlines this morning.", "url": "https://www.zacks.com/commentary/2251416/acquisition-watch-time-to-buy-johnson-johnson-jnj-or-shockwave-medical-s-swav-stock?cid=CS-STOCKNEWSAPI-FT-investment_ideas-2251416", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-05T16:31:04-04:00", "date_et": "2024-04-05"}
{"symbol": "JNJ", "publishedDate": "2024-04-05 23:21:00", "publisher": "PRNewsWire", "title": "CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy", "image": "https://images.financialmodelingprep.com/news/carvykti-is-the-first-and-only-bcmatargeted-treatment-approved-20240405.jpg", "site": "prnewswire.com", "text": "Expanded indication for this one-time infusion will provide more patients with a potential period away from their multiple myeloma treatment as early as first relapse Approval is based on results from the Phase 3 CARTITUDE-4 study, in which treatment with CARVYKTI ® in 1-3 prior lines of therapy reduced the risk of disease progression or death by 59 percent compared to standard therapies HORSHAM, Pa. , April 5, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.1 With this approval, CARVYKTI® becomes the first and only B-cell maturation antigen (BCMA)-targeted therapy approved for the treatment of patients with multiple myeloma as early as first relapse.", "url": "https://www.prnewswire.com/news-releases/carvykti-is-the-first-and-only-bcma-targeted-treatment-approved-by-the-us-fda-for-patients-with-relapsed-or-refractory-multiple-myeloma-who-have-received-at-least-one-prior-line-of-therapy-302109706.html", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-05T23:21:00-04:00", "date_et": "2024-04-05"}
{"symbol": "JNJ", "publishedDate": "2024-04-05 23:43:38", "publisher": "Reuters", "title": "U.S. FDA approves expanded use of J&J's cancer cell therapy", "image": "https://images.financialmodelingprep.com/news/us-fda-approves-expanded-use-of-jjs-cancer-cell-20240405.jpg", "site": "reuters.com", "text": "The U.S. Food and Drug Administration on Friday allowed the expanded use of Johnson & Johnson and Legend Biotech's Carvykti cell therapy as an earlier treatment for patients with a type of blood cancer.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-expanded-use-jjs-cancer-cell-therapy-2024-04-06/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-05T23:43:38-04:00", "date_et": "2024-04-05"}
{"symbol": "JNJ", "publishedDate": "2024-04-06 05:50:00", "publisher": "Seeking Alpha", "title": "U.S. IPO Weekly Recap: April IPO Market Gets A Boost From Large Launches And New Filings", "image": "https://images.financialmodelingprep.com/news/us-ipo-weekly-recap-april-ipo-market-gets-a-20240406.jpg", "site": "seekingalpha.com", "text": "Three IPOs priced in the first week of April, led by a sizable biotech. Two sizable listings are currently scheduled for the week ahead, although smaller issuers may join the calendar throughout the week.", "url": "https://seekingalpha.com/article/4682489-us-ipo-weekly-recap-april-ipo-market-gets-boost-from-large-launches-and-new-filings", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-06T05:50:00-04:00", "date_et": "2024-04-06"}
{"symbol": "JNJ", "publishedDate": "2024-04-08 07:30:50", "publisher": "Forbes", "title": "Is Johnson & Johnson Stock A Better Pick Over AbbVie?", "image": "https://images.financialmodelingprep.com/news/is-johnson-johnson-stock-a-better-pick-over-abbvie-20240408.jpg", "site": "forbes.com", "text": "We believe that the pharmaceuticals bellwether Johnson & Johnson (NYSE: JNJ) is currently a better pick over its peer AbbVie (NYSE: ABBV). AbbVie ABBV trades at a higher valuation of 5.5x trailing revenues, compared to 4.6x for JNJ.", "url": "https://www.forbes.com/sites/greatspeculations/2024/04/08/is-johnson--johnson-stock-a-better-pick-over-abbvie/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-08T07:30:50-04:00", "date_et": "2024-04-08"}
{"symbol": "JNJ", "publishedDate": "2024-04-08 10:21:09", "publisher": "Zacks Investment Research", "title": "J&J's (JNJ) $13.1B Shockwave Deal to Boost MedTech Cardio", "image": "https://images.financialmodelingprep.com/news/jjs-jnj-131b-shockwave-deal-to-boost-medtech-cardio-20240408.jpg", "site": "zacks.com", "text": "J&J's (JNJ) proposed acquisition of Shockwave Medical (SWAV) is expected to strengthen its Medtech cardiovascular portfolio.", "url": "https://www.zacks.com/stock/news/2251822/j-j-s-jnj-13-1b-shockwave-deal-to-boost-medtech-cardio?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_-_medical_sector-2251822", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-08T10:21:09-04:00", "date_et": "2024-04-08"}
{"symbol": "JNJ", "publishedDate": "2024-04-08 10:41:27", "publisher": "Zacks Investment Research", "title": "FDA Expands J&J's (JNJ) Carvykti Label in Multiple Myeloma", "image": "https://images.financialmodelingprep.com/news/fda-expands-jjs-jnj-carvykti-label-in-multiple-myeloma-20240408.jpg", "site": "zacks.com", "text": "Following the label expansion, J&J's (JNJ) Carvykti is approved as a second-line treatment for adults with relapsed/refractory myeloma. It was initially approved for use as a fifth- or later-line treatment.", "url": "https://www.zacks.com/stock/news/2252028/fda-expands-j-j-s-jnj-carvykti-label-in-multiple-myeloma?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_-_medical_sector-2252028", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-08T10:41:27-04:00", "date_et": "2024-04-08"}
{"symbol": "JNJ", "publishedDate": "2024-04-08 11:55:08", "publisher": "MarketBeat", "title": "Will the Shockwave Medical Deal Be the Jolt JNJ Stock Needs?", "image": "https://images.financialmodelingprep.com/news/will-the-shockwave-medical-deal-be-the-jolt-jnj-stock-20240408.jpg", "site": "marketbeat.com", "text": "On April 5, 2024, Johnson & Johnson NYSE: JNJ announced its intent to acquire Shockwave Medical Inc. NASDAQ: SWAV for $13.1 billion. Under the terms of the proposed deal, JNJ will pay $335 per share, which is a 4.75% premium compared to Shockwave's closing price on April 4, 2024.", "url": "https://www.marketbeat.com/originals/will-the-shockwave-medical-deal-be-the-jolt-jnj-stock-needs/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-08T11:55:08-04:00", "date_et": "2024-04-08"}
{"symbol": "JNJ", "publishedDate": "2024-04-08 11:55:08", "publisher": "MarketBeat", "title": "Will the Shockwave Medical Deal Be the Jolt JNJ Stock Needs?", "image": "https://images.financialmodelingprep.com/news/will-the-shockwave-medical-deal-be-the-jolt-jnj-20240408.jpg", "site": "marketbeat.com", "text": "On April 5, 2024, Johnson & Johnson NYSE: JNJ announced its intent to acquire Shockwave Medical Inc. NASDAQ: SWAV for $13.1 billion. Under the terms of the proposed deal, JNJ will pay $335 per share, which is a 4.75% premium compared to Shockwave's closing price on April 4, 2024.", "url": "https://www.marketbeat.com/originals/will-the-shockwave-medical-deal-be-the-jolt-jnj-stock-needs/?utm_source=snapi", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-08T11:55:08-04:00", "date_et": "2024-04-08"}
{"symbol": "JNJ", "publishedDate": "2024-04-08 18:06:00", "publisher": "Business Wire", "title": "Johnson & Johnson to Participate in the 2024 RBC Capital Markets Global Healthcare Conference", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-to-participate-in-the-2024-rbc-capital-20240408.jpg", "site": "businesswire.com", "text": "NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the 2024 RBC Capital Markets Global Healthcare Conference on Wednesday, May 15th, at the InterContinental Barclay Hotel, New York. Tim Schmid, Executive Vice President, Worldwide Chairman, MedTech, will represent the Company in a session scheduled at 11:00 am (Eastern Time). This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website.", "url": "https://www.businesswire.com/news/home/20240408576293/en/Johnson-Johnson-to-Participate-in-the-2024-RBC-Capital-Markets-Global-Healthcare-Conference/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-08T18:06:00-04:00", "date_et": "2024-04-08"}
{"symbol": "JNJ", "publishedDate": "2024-04-08 18:56:11", "publisher": "Zacks Investment Research", "title": "Here's Why Johnson & Johnson (JNJ) Fell More Than Broader Market", "image": "https://images.financialmodelingprep.com/news/heres-why-johnson-johnson-jnj-fell-more-than-broader-20240408.jpg", "site": "zacks.com", "text": "In the latest trading session, Johnson & Johnson (JNJ) closed at $151.59, marking a -0.52% move from the previous day.", "url": "https://www.zacks.com/stock/news/2252223/here-s-why-johnson-johnson-jnj-fell-more-than-broader-market?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_6v1-2252223", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-08T18:56:11-04:00", "date_et": "2024-04-08"}
{"symbol": "JNJ", "publishedDate": "2024-04-08 20:49:00", "publisher": "Business Wire", "title": "SHOCKWAVE MEDICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Shockwave Medical, Inc. - SWAV", "image": "https://images.financialmodelingprep.com/news/shockwave-medical-investor-alert-by-the-former-attorney-general-20240408.jpg", "site": "businesswire.com", "text": "NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Shockwave Medical, Inc. (NasdaqGS: SWAV) to Johnson & Johnson (NYSE: JNJ). Under the terms of the proposed transaction, shareholders of Shockwave will receive $335.00 in cash for each share of Shockwave that they own. KSF is seeking to determine whether this consideration and the process that led to it are.", "url": "https://www.businesswire.com/news/home/20240408057780/en/SHOCKWAVE-MEDICAL-INVESTOR-ALERT-by-the-Former-Attorney-General-of-Louisiana-Kahn-Swick-Foti-LLC-Investigates-Adequacy-of-Price-and-Process-in-Proposed-Sale-of-Shockwave-Medical-Inc.---SWAV/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-08T20:49:00-04:00", "date_et": "2024-04-08"}
{"symbol": "JNJ", "publishedDate": "2024-04-09 04:21:00", "publisher": "The Motley Fool", "title": "3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade", "image": "https://images.financialmodelingprep.com/news/3-dividend-growth-stocks-with-yields-above-3-that-you-20240409.jpg", "site": "fool.com", "text": "AbbVie's dividend payout has more than tripled over the past decade, and it could soar much further in the decade ahead. Bristol Myers Squibb offers a juicy 4.7% dividend yield at recent prices.", "url": "https://www.fool.com/investing/2024/04/09/3-dividend-growth-stocks-with-yields-above-3-that/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-09T04:21:00-04:00", "date_et": "2024-04-09"}
{"symbol": "JNJ", "publishedDate": "2024-04-09 11:06:03", "publisher": "Zacks Investment Research", "title": "Johnson & Johnson (JNJ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-jnj-expected-to-beat-earnings-estimates-can-20240409.jpg", "site": "zacks.com", "text": "Johnson & Johnson (JNJ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.", "url": "https://www.zacks.com/stock/news/2252668/johnson-johnson-jnj-expected-to-beat-earnings-estimates-can-the-stock-move-higher?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_9-2252668", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-09T11:06:03-04:00", "date_et": "2024-04-09"}
{"symbol": "JNJ", "publishedDate": "2024-04-09 14:37:54", "publisher": "CNBC", "title": "Healthy Returns: J&J cell therapy gains new edge over Bristol Myers rival", "image": "https://images.financialmodelingprep.com/news/healthy-returns-jj-cell-therapy-gains-new-edge-over-20240409.jpeg", "site": "cnbc.com", "text": "J&J's cell therapy is now approved for an earlier line of treatment than a competing drug from Bristol Myers. Meanwhile, a look at Mount Sinai's approach to AI.", "url": "https://www.cnbc.com/2024/04/09/healthy-returns-jj-cell-therapy-gains-edge-over-bristol-myers-rival.html", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-09T14:37:54-04:00", "date_et": "2024-04-09"}
{"symbol": "JNJ", "publishedDate": "2024-04-10 04:57:00", "publisher": "The Motley Fool", "title": "Does Johnson & Johnson's Latest Acquisition Make It a No-Brainer Buy?", "image": "https://images.financialmodelingprep.com/news/does-johnson-johnsons-latest-acquisition-make-it-a-nobrainer-buy-20240410.jpeg", "site": "fool.com", "text": "Johnson & Johnson is buying Shockwave Medical for $13.1 billion. Shockwave is a profitable company that expects to generate more than $900 million in sales this year.", "url": "https://www.fool.com/investing/2024/04/10/jnj-stock-acquisition-make-no-brainer-buy/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-10T04:57:00-04:00", "date_et": "2024-04-10"}
{"symbol": "JNJ", "publishedDate": "2024-04-10 06:25:00", "publisher": "InvestorPlace", "title": "If You Can Only Buy One Dividend Stock in April, It Better Be One of These 3 Names", "image": "https://images.financialmodelingprep.com/news/if-you-can-only-buy-one-dividend-stock-in-april-20240410.jpg", "site": "investorplace.com", "text": "Looking ahead, the future of the US economy is shaped by ongoing debates over interest rate policy and inflation. Recent robust economic data has led investors to anticipate fewer interest rate cuts by the U.S. Federal Reserve in 2024.", "url": "https://investorplace.com/2024/04/if-you-can-only-buy-one-dividend-stock-in-april-it-better-be-one-of-these-3-names/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-10T06:25:00-04:00", "date_et": "2024-04-10"}
{"symbol": "JNJ", "publishedDate": "2024-04-10 08:30:12", "publisher": "Forbes", "title": "What's Next For Johnson & Johnson Stock After A 6% Decline In A Month?", "image": "https://images.financialmodelingprep.com/news/whats-next-for-johnson-johnson-stock-after-a-6-20240410.jpg", "site": "forbes.com", "text": "Johnson & Johnson (NYSE: JNJ) recently announced its plans to acquire Shockwave Medical for $13 billion. Shockwave will help J&J extend its offerings in the cardiovascular intervention market.", "url": "https://www.forbes.com/sites/greatspeculations/2024/04/10/whats-next-for-johnson--johnson-stock-after-a-6-decline-in-a-month/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-10T08:30:12-04:00", "date_et": "2024-04-10"}
{"symbol": "JNJ", "publishedDate": "2024-04-10 11:50:03", "publisher": "Reuters", "title": "Nigeria recalls J&J children's cough syrup over toxic substance", "image": "https://images.financialmodelingprep.com/news/nigeria-recalls-jj-childrens-cough-syrup-over-toxic-substance-20240410.jpg", "site": "reuters.com", "text": "Nigeria's health regulator is recalling a batch of Johnson & Johnson children's cough syrup after finding an unacceptably high level of a potentially fatal toxic substance, it said on Wednesday.", "url": "https://www.reuters.com/world/africa/nigeria-recalls-jj-childrens-cough-syrup-over-toxic-substance-2024-04-10/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-10T11:50:03-04:00", "date_et": "2024-04-10"}
{"symbol": "JNJ", "publishedDate": "2024-04-10 13:22:18", "publisher": "InvestorPlace", "title": "7 Healthcare Stocks to Keep Your Portfolio in Tip-Top Shape", "image": "https://images.financialmodelingprep.com/news/7-healthcare-stocks-to-keep-your-portfolio-in-tiptop-20240410.jpg", "site": "investorplace.com", "text": "With rising concerns in the market potentially forcing a strategic shift, investors may want to consider healthcare stocks. No matter what happens, people need access to health-related products and services.", "url": "https://investorplace.com/2024/04/7-healthcare-stocks-to-keep-your-portfolio-in-tip-top-shape/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-10T13:22:18-04:00", "date_et": "2024-04-10"}
{"symbol": "JNJ", "publishedDate": "2024-04-10 17:45:00", "publisher": "InvestorPlace", "title": "Wall Street Favorites: 3 Dividend Stocks With Strong Buy Ratings for April 2024", "image": "https://images.financialmodelingprep.com/news/wall-street-favorites-3-dividend-stocks-with-strong-buy-20240410.jpg", "site": "investorplace.com", "text": "The dividend kings are a select group of dividend stocks made up of companies that have increased their dividends for at least 50 consecutive years. That may be a throw-away statistic.", "url": "https://investorplace.com/2024/04/wall-street-favorites-3-dividend-stocks-with-strong-buy-ratings-for-april-2024/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-10T17:45:00-04:00", "date_et": "2024-04-10"}
{"symbol": "JNJ", "publishedDate": "2024-04-11 10:06:19", "publisher": "Zacks Investment Research", "title": "Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know", "image": "https://images.financialmodelingprep.com/news/investors-heavily-search-johnson-johnson-jnj-here-is-what-20240411.jpg", "site": "zacks.com", "text": "Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.", "url": "https://www.zacks.com/stock/news/2253803/investors-heavily-search-johnson-johnson-jnj-here-is-what-you-need-to-know?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|most_searched_stocks-2253803", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-11T10:06:19-04:00", "date_et": "2024-04-11"}
{"symbol": "JNJ", "publishedDate": "2024-04-11 10:16:03", "publisher": "Reuters", "title": "Kenya recalls J&J children's cough syrup over suspected toxicity", "image": "https://images.financialmodelingprep.com/news/kenya-recalls-jj-childrens-cough-syrup-over-suspected-toxicity-20240411.jpg", "site": "reuters.com", "text": "Kenya's drug regulator is recalling a batch of Johnson & Johnson children's cough syrup, it said on Thursday, a day after Nigeria recalled the same batch of medication under the Benylin Paediatric brand.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/kenya-recalls-jj-childrens-cough-syrup-over-suspected-toxicity-2024-04-11/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-11T10:16:03-04:00", "date_et": "2024-04-11"}
{"symbol": "JNJ", "publishedDate": "2024-04-11 10:20:36", "publisher": "Zacks Investment Research", "title": "Unlocking Q1 Potential of Johnson & Johnson (JNJ): Exploring Wall Street Estimates for Key Metrics", "image": "https://images.financialmodelingprep.com/news/unlocking-q1-potential-of-johnson-johnson-jnj-exploring-wall-20240411.jpg", "site": "zacks.com", "text": "Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Johnson & Johnson (JNJ), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.", "url": "https://www.zacks.com/stock/news/2253845/unlocking-q1-potential-of-johnson-johnson-jnj-exploring-wall-street-estimates-for-key-metrics?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|nfm_preview-2253845", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-11T10:20:36-04:00", "date_et": "2024-04-11"}
{"symbol": "JNJ", "publishedDate": "2024-04-11 11:32:51", "publisher": "Proactive Investors", "title": "Rallybio partners with J&J to advance therapies targeting rare fetal disease", "image": "https://images.financialmodelingprep.com/news/rallybio-partners-with-jj-to-advance-therapies-targeting-rare-fetal-20240411.jpg", "site": "proactiveinvestors.com", "text": "Rallybio announced it is collaborating with Johnson & Johnson (NYSE:JNJ) on the development of therapies aimed at reducing the risk of a rare fetal disease called fetal and neonatal alloimmune thrombocytopenia (FNAIT). Shares of the biotechnology company soared on the announcement, adding 69.3% at $2.76 late morning on Thursday.", "url": "https://www.proactiveinvestors.com/companies/news/1045123", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-11T11:32:51-04:00", "date_et": "2024-04-11"}
{"symbol": "JNJ", "publishedDate": "2024-04-11 11:32:51", "publisher": "Proactive Investors", "title": "Rallybio partners with J&J to advance therapies targeting rare fetal disease", "image": "https://images.financialmodelingprep.com/news/rallybio-partners-with-jj-to-advance-therapies-targeting-rare-20240411.jpg", "site": "proactiveinvestors.com", "text": "Rallybio announced it is collaborating with Johnson & Johnson (NYSE:JNJ) on the development of therapies aimed at reducing the risk of a rare fetal disease called fetal and neonatal alloimmune thrombocytopenia (FNAIT). Shares of the biotechnology company soared on the announcement, adding 69.3% at $2.76 late morning on Thursday.", "url": "https://www.proactiveinvestors.com/companies/news/1045123?SNAPI", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-11T11:32:51-04:00", "date_et": "2024-04-11"}
{"symbol": "JNJ", "publishedDate": "2024-04-11 12:17:59", "publisher": "InvestorPlace", "title": "All-Time High Flyers: 7 Stocks to Buy as the Market Peaks", "image": "https://images.financialmodelingprep.com/news/alltime-high-flyers-7-stocks-to-buy-as-the-20240411.jpg", "site": "investorplace.com", "text": "If you're wondering which stocks to buy in April, here's a good place to start. The stock market is off to a difficult start in the second quarter.", "url": "https://investorplace.com/2024/04/all-time-high-flyers-7-stocks-to-buy-as-the-market-peaks/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-11T12:17:59-04:00", "date_et": "2024-04-11"}
{"symbol": "JNJ", "publishedDate": "2024-04-11 13:10:22", "publisher": "InvestorPlace", "title": "Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024", "image": "https://images.financialmodelingprep.com/news/wall-street-favorites-3-biotech-stocks-with-strong-buy-20240411.png", "site": "investorplace.com", "text": "Biotech stocks were among the worst performers in 2023. And so far in 2024, investors are still waiting on the recovery rally.", "url": "https://investorplace.com/2024/04/wall-street-favorites-3-biotech-stocks-with-strong-buy-ratings-for-april-2024/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-11T13:10:22-04:00", "date_et": "2024-04-11"}
{"symbol": "JNJ", "publishedDate": "2024-04-11 13:35:59", "publisher": "Proactive Investors", "title": "Johnson & Johnson expected to face dip in first-quarter earnings", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-expected-to-face-dip-in-firstquarter-earnings-20240411.jpg", "site": "proactiveinvestors.com", "text": "Johnson & Johnson (NYSE:JNJ) will report first quarter results next Tuesday, 16 April, hot on the heels of its acquisition of Shockwave Medical. This US$13.1 billion deal saw J&J move further into the cardiovascular intervention market, under wider plans to enter “higher growth” sectors, the pharmaceutical giant said at the time.", "url": "https://www.proactiveinvestors.com/companies/news/1045132?SNAPI", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-11T13:35:59-04:00", "date_et": "2024-04-11"}
{"symbol": "JNJ", "publishedDate": "2024-04-11 13:35:59", "publisher": "Proactive Investors", "title": "Johnson & Johnson expected to face dip in first-quarter earnings", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-expected-to-face-dip-in-firstquarter-earnings-20240411.jpg", "site": "proactiveinvestors.com", "text": "Johnson & Johnson (NYSE:JNJ) will report first quarter results next Tuesday, 16 April, hot on the heels of its acquisition of Shockwave Medical. This US$13.1 billion deal saw J&J move further into the cardiovascular intervention market, under wider plans to enter “higher growth” sectors, the pharmaceutical giant said at the time.", "url": "https://www.proactiveinvestors.com/companies/news/1045132", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-11T13:35:59-04:00", "date_et": "2024-04-11"}
{"symbol": "JNJ", "publishedDate": "2024-04-12 08:00:00", "publisher": "Seeking Alpha", "title": "Johnson & Johnson: Doubling Down On This 2024 Dog Of The Dow", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-doubling-down-on-this-2024-dog-of-20240412.jpg", "site": "seekingalpha.com", "text": "Johnson & Johnson (JNJ) is positioned to gain on the upside due to solid financials, consistent dividend streak, and potential increase in healthcare spending.", "url": "https://seekingalpha.com/article/4683388-johnson-and-johnson-doubling-down-on-this-2024-dog-of-the-dow-jnj-stock", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-12T08:00:00-04:00", "date_et": "2024-04-12"}
{"symbol": "JNJ", "publishedDate": "2024-04-12 10:11:06", "publisher": "Zacks Investment Research", "title": "J&J (JNJ) to Begin Pharma Q1 Earnings Season: What's in Store?", "image": "https://images.financialmodelingprep.com/news/jj-jnj-to-begin-pharma-q1-earnings-season-whats-20240412.jpg", "site": "zacks.com", "text": "J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.", "url": "https://www.zacks.com/stock/news/2254365/j-j-jnj-to-begin-pharma-q1-earnings-season-what-s-in-store?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_preview-2254365", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-12T10:11:06-04:00", "date_et": "2024-04-12"}
{"symbol": "JNJ", "publishedDate": "2024-04-12 14:39:25", "publisher": "Seeking Alpha", "title": "55 April Dividend Kings: Buy 8, Watch 8", "image": "https://images.financialmodelingprep.com/news/55-april-dividend-kings-buy-8-watch-8-20240412.jpg", "site": "seekingalpha.com", "text": "\"What is a Dividend King? A stock with 50 or more consecutive years of dividend increases.\"—suredividend.com. The 55 Dividend Kings screened as of April 10 represented 9 of 11 Morningstar Sectors. Broker targeted-top-ten net-gains ranged 15.19%-33.38% topped-by Middlesex Water, and SJW Group. By yield, Leggett tops-all. Top-ten April Kings: FRT, UBSI, FTS, BKH, NWN, CDUAF, MMM, UVV, MO, & LEG averaged 6.24% in yield.", "url": "https://seekingalpha.com/article/4683516-55-april-dividend-kings-buy-8-watch-8", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-12T14:39:25-04:00", "date_et": "2024-04-12"}
{"symbol": "JNJ", "publishedDate": "2024-04-12 16:01:04", "publisher": "Zacks Investment Research", "title": "3 Quarterly Releases to Watch Next Week", "image": "https://images.financialmodelingprep.com/news/3-quarterly-releases-to-watch-next-week-20240412.jpg", "site": "zacks.com", "text": "Earnings season is always an exciting time for investors, with companies finally revealing what's transpired behind closed doors. And concerning next week's docket, these three notable companies are scheduled to report.", "url": "https://www.zacks.com/stock/news/2254814/3-quarterly-releases-to-watch-next-week?cid=CS-STOCKNEWSAPI-FT-stocks_in_the_news-2254814", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-12T16:01:04-04:00", "date_et": "2024-04-12"}
{"symbol": "JNJ", "publishedDate": "2024-04-13 14:50:00", "publisher": "Reuters", "title": "South Africa recalls J&J's cough syrup sold in six African nations after suspected toxicity", "image": "https://images.financialmodelingprep.com/news/south-africa-recalls-jjs-cough-syrup-sold-in-six-20240413.jpg", "site": "reuters.com", "text": "South Africa's health regulator said on Saturday it is recalling batches of Johnson & Johnson's children's cough syrup after detection of high levels of diethylene glycol.", "url": "https://www.reuters.com/world/africa/south-africa-recalls-jjs-cough-syrup-sold-six-african-nations-after-suspected-2024-04-13/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-13T14:50:00-04:00", "date_et": "2024-04-13"}
{"symbol": "JNJ", "publishedDate": "2024-04-14 09:00:00", "publisher": "InvestorPlace", "title": "The 3 Best Stocks to Buy to Survive the Coming S&P 500 Crash", "image": "https://images.financialmodelingprep.com/news/the-3-best-stocks-to-buy-to-survive-the-20240414.png", "site": "investorplace.com", "text": "The S&P 500 is doing great this year after last year's historic run higher. The broad index is up almost 9% in 2024.", "url": "https://investorplace.com/2024/04/the-3-best-stocks-to-buy-to-survive-the-coming-sp-500-crash/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-14T09:00:00-04:00", "date_et": "2024-04-14"}
{"symbol": "JNJ", "publishedDate": "2024-04-15 07:04:10", "publisher": "Reuters", "title": "Rwanda joins other African countries in recalling J&J children's cough syrup", "image": "https://images.financialmodelingprep.com/news/rwanda-joins-other-african-countries-in-recalling-jj-childrens-20240415.jpg", "site": "reuters.com", "text": "Rwanda's drug regulator has recalled a batch of Johnson & Johnson children's cough syrup as a precautionary measure after its Nigerian counterpart said laboratory tests found high levels of toxicity.", "url": "https://www.reuters.com/world/africa/rwanda-joins-other-african-countries-recalling-jj-childrens-cough-syrup-2024-04-15/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-15T07:04:10-04:00", "date_et": "2024-04-15"}
{"symbol": "JNJ", "publishedDate": "2024-04-15 09:21:12", "publisher": "Zacks Investment Research", "title": "5 U.S. Bigwigs Likely to Gain on Q1 Earnings Beat This Week", "image": "https://images.financialmodelingprep.com/news/5-us-bigwigs-likely-to-gain-on-q1-earnings-20240415.jpg", "site": "zacks.com", "text": "We have narrowed our search to five large-cap stocks that are poised to beat on earnings results this week. These are: BAC, JNJ, UAL, PNC, BK.", "url": "https://www.zacks.com/stock/news/2255174/5-u-s-bigwigs-likely-to-gain-on-q1-earnings-beat-this-week?cid=CS-STOCKNEWSAPI-FT-earnings_esp-2255174", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-15T09:21:12-04:00", "date_et": "2024-04-15"}
{"symbol": "JNJ", "publishedDate": "2024-04-15 09:56:44", "publisher": "Reuters", "title": "Tanzania, Rwanda join African recall of J&J children's cough syrup", "image": "https://images.financialmodelingprep.com/news/tanzania-rwanda-join-african-recall-of-jj-childrens-cough-20240415.jpg", "site": "reuters.com", "text": "Drug regulators in Tanzania and Rwanda have recalled a batch of Johnson & Johnson children's cough syrup as a precautionary measure after their Nigerian counterpart said laboratory tests found high levels of toxicity.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/tanzania-rwanda-join-african-recall-jj-childrens-cough-syrup-2024-04-15/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-15T09:56:44-04:00", "date_et": "2024-04-15"}
{"symbol": "JNJ", "publishedDate": "2024-04-15 10:23:40", "publisher": "Stockmarketcom", "title": "3 Blue Chip Stocks For Your April 2024 Watchlist", "image": "https://images.financialmodelingprep.com/news/3-blue-chip-stocks-for-your-april-2024-watchlist-20240415.jpg", "site": "stockmarket.com", "text": "Blue Chip stocks to watch in the stock market today.", "url": "https://stockmarket.com/featured/3-blue-chip-stocks-for-your-april-2024-watchlist-2024-04-15", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-15T10:23:40-04:00", "date_et": "2024-04-15"}
{"symbol": "JNJ", "publishedDate": "2024-04-15 10:32:00", "publisher": "Barrons", "title": "Johnson & Johnson Reports Earnings Tuesday. What to Expect.", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-reports-earnings-tuesday-what-to-expect-20240415.jpg", "site": "barrons.com", "text": "Pharmaceuticals firm Johnson & Johnson kicks off earnings season for the sector on Tuesday. Investors want executives to put to rest ongoing talc litigation.", "url": "https://www.barrons.com/articles/johnson-johnson-earnings-stock-preview-51a43535", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-15T10:32:00-04:00", "date_et": "2024-04-15"}
{"symbol": "JNJ", "publishedDate": "2024-04-15 11:00:40", "publisher": "Forbes", "title": "Here's What To Expect From Johnson & Johnson's Q1", "image": "https://images.financialmodelingprep.com/news/heres-what-to-expect-from-johnson-johnsons-q1-20240415.jpg", "site": "forbes.com", "text": "Johnson & Johnson stock (NYSE: JNJ) will report its Q1 2024 results on Tuesday, April 16. We expect the company to post revenue of $21.5 billion and earnings of $2.68, compared to the consensus estimates of $21.4 billion and $2.64, respectively.", "url": "https://www.forbes.com/sites/greatspeculations/2024/04/15/heres-what-to-expect-from-johnson--johnsons-q1/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-15T11:00:40-04:00", "date_et": "2024-04-15"}
{"symbol": "JNJ", "publishedDate": "2024-04-15 11:11:05", "publisher": "Zacks Investment Research", "title": "Should You Buy Johnson & Johnson (JNJ) Ahead of Earnings?", "image": "https://images.financialmodelingprep.com/news/should-you-buy-johnson-johnson-jnj-ahead-of-earnings-20240415.jpg", "site": "zacks.com", "text": "Johnson & Johnson (JNJ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.", "url": "https://www.zacks.com/stock/news/2255431/should-you-buy-johnson-johnson-jnj-ahead-of-earnings?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|earnings_surprise-2255431", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-15T11:11:05-04:00", "date_et": "2024-04-15"}
{"symbol": "JNJ", "publishedDate": "2024-04-16 06:20:00", "publisher": "Business Wire", "title": "Johnson & Johnson Reports Q1 2024 Results", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-reports-q1-2024-results-20240416.jpg", "site": "businesswire.com", "text": "NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2024. “Johnson & Johnson's solid first quarter performance reflects our sharpened focus and the progress in our portfolio and pipeline,” said Joaquin Duato, Chairman and Chief Executive Officer. “Our impact across the full spectrum of healthcare is unique in our industry, and the milestones achieved this quarter reinforce our position as an innovation powerhouse.” Unless otherwi.", "url": "https://www.businesswire.com/news/home/20240416019157/en/Johnson-Johnson-Reports-Q1-2024-Results/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-16T06:20:00-04:00", "date_et": "2024-04-16"}
{"symbol": "JNJ", "publishedDate": "2024-04-16 06:22:57", "publisher": "Reuters", "title": "J&J beats first-quarter profit estimates on cancer drugs strength", "image": "https://images.financialmodelingprep.com/news/jj-beats-firstquarter-profit-estimates-on-cancer-drugs-strength-20240416.jpg", "site": "reuters.com", "text": "Johnson & Johnson reported a first-quarter profit above Wall Street estimates on Tuesday, helped by strong sales of its cancer drugs including top-selling blood cancer treatment Darzalex.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/jj-beats-first-quarter-profit-estimates-cancer-drugs-strength-2024-04-16/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-16T06:22:57-04:00", "date_et": "2024-04-16"}
{"symbol": "JNJ", "publishedDate": "2024-04-16 06:24:08", "publisher": "CNBC", "title": "Johnson & Johnson tops quarterly profit estimates as medical device sales jump", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-tops-quarterly-profit-estimates-as-medical-device-20240416.jpeg", "site": "cnbc.com", "text": "The company is benefiting from a rebound in demand for nonurgent surgeries among older adults, who deferred those procedures during the Covid pandemic.", "url": "https://www.cnbc.com/2024/04/16/johnson-johnson-jnj-earnings-q1-2024.html", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-16T06:24:08-04:00", "date_et": "2024-04-16"}
{"symbol": "JNJ", "publishedDate": "2024-04-16 06:25:00", "publisher": "Business Wire", "title": "Johnson & Johnson Announces 62nd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.2%", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-announces-62nd-consecutive-year-of-dividend-increase-20240416.jpg", "site": "businesswire.com", "text": "NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 4.2% increase in the quarterly dividend, from $1.19 per share to $1.24 per share, marking the 62nd year of consecutive increases. At the new rate, the indicated dividend on an annual basis is $4.96 per share compared to the previous rate of $4.76 per share. The next quarterly dividend is payable on June 4, 2024 to shareholders of record at the close of business on M.", "url": "https://www.businesswire.com/news/home/20240416660427/en/Johnson-Johnson-Announces-62nd-Consecutive-Year-of-Dividend-Increase-Raises-Quarterly-Dividend-by-4.2/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-16T06:25:00-04:00", "date_et": "2024-04-16"}
{"symbol": "JNJ", "publishedDate": "2024-04-16 06:32:00", "publisher": "Market Watch", "title": "Johnson & Johnon's Q1 profit beats as sales fall slightly short of estimates", "image": "https://images.financialmodelingprep.com/news/johnson-johnons-q1-profit-beats-as-sales-fall-slightly-20240416.jpeg", "site": "marketwatch.com", "text": "Johnson & Johnson's stock JNJ, +0.05% fell 0.4% early Tuesday, after the healthcare company posted better-than-expected profit for the first quarter but sales that fell slightly short of expectations. The New Brunswick, N.J.", "url": "https://www.marketwatch.com/story/johnson-johnons-q1-profit-beats-as-sales-fall-slightly-short-of-estimates-183b9a70", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-16T06:32:00-04:00", "date_et": "2024-04-16"}
{"symbol": "JNJ", "publishedDate": "2024-04-16 06:56:55", "publisher": "Invezz", "title": "Earnings turnaround for Johnson & Johnson with Q1 2024 financial results", "image": "https://images.financialmodelingprep.com/news/earnings-turnaround-for-johnson-johnson-with-q1-2024-financial-20240416.jpg", "site": "invezz.com", "text": "Pharmaceutical and consumer staples titan Johnson & Johnson reported its Q1 2024 financial results before US markets opened this morning. Johnson & Johnson announced significant turnaround in its net earnings, with $5.3 billion in net earnings for Q1 from continuing operations, versus the $491 million loss of Q1 2023 for the same category.", "url": "https://invezz.com/news/2024/04/16/earnings-turnaround-for-johnson-johnson-with-q1-2024-financial-results/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-16T06:56:55-04:00", "date_et": "2024-04-16"}
{"symbol": "JNJ", "publishedDate": "2024-04-16 08:05:20", "publisher": "24/7 Wall Street", "title": "6 Dividend Aristocrats to Buy for Reliable Passive Income", "image": "https://images.financialmodelingprep.com/news/6-dividend-aristocrats-to-buy-for-reliable-passive-income-20240416.jpg", "site": "247wallst.com", "text": "Its products are sold under these brands: Exxon Esso Mobil  The Chemical Products segment manufactures and markets petrochemicals, including olefins, polyolefins, and intermediates.", "url": "https://247wallst.com/investing/2024/04/16/6-dividend-aristocrats-to-buy-for-reliable-passive-income/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-16T08:05:20-04:00", "date_et": "2024-04-16"}
{"symbol": "JNJ", "publishedDate": "2024-04-16 08:05:20", "publisher": "24/7 Wall Street", "title": "6 Dividend Aristocrats to Buy for Reliable Passive Income", "image": "https://images.financialmodelingprep.com/news/6-dividend-aristocrats-to-buy-for-reliable-passive-income-20240416.jpg", "site": "247wallst.com", "text": "Its products are sold under these brands: Exxon Esso Mobil  The Chemical Products segment manufactures and markets petrochemicals, including olefins, polyolefins, and intermediates.", "url": "https://247wallst.com/investing/2024/04/16/6-dividend-aristocrats-to-buy-for-reliable-passive-income/?utm_source=snapi", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-16T08:05:20-04:00", "date_et": "2024-04-16"}
{"symbol": "JNJ", "publishedDate": "2024-04-16 08:31:04", "publisher": "Zacks Investment Research", "title": "Johnson & Johnson (JNJ) Q1 Earnings Top Estimates", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-jnj-q1-earnings-top-estimates-20240416.jpg", "site": "zacks.com", "text": "Johnson & Johnson (JNJ) came out with quarterly earnings of $2.71 per share, beating the Zacks Consensus Estimate of $2.64 per share. This compares to earnings of $2.68 per share a year ago.", "url": "https://www.zacks.com/stock/news/2255793/johnson-johnson-jnj-q1-earnings-top-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2255793", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-16T08:31:04-04:00", "date_et": "2024-04-16"}
{"symbol": "JNJ", "publishedDate": "2024-04-16 09:06:45", "publisher": "Reuters", "title": "Nigerian regulator: no record of child deaths from recalled J&J cough syrup", "image": "https://images.financialmodelingprep.com/news/nigerian-regulator-no-record-of-child-deaths-from-recalled-20240416.jpg", "site": "reuters.com", "text": "A senior official at Nigeria's drug regulator said on Tuesday that the regulator had no record of children dying from a batch of cough syrup manufactured by Johnson & Johnson which had been recalled.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/nigerian-regulator-no-record-child-deaths-recalled-jj-cough-syrup-2024-04-16/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-16T09:06:45-04:00", "date_et": "2024-04-16"}
{"symbol": "JNJ", "publishedDate": "2024-04-16 09:15:49", "publisher": "MarketBeat", "title": "Johnson & Johnson is as Cheap as it's Going to Get", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-is-as-cheap-as-its-going-to-get-20240416.jpg", "site": "marketbeat.com", "text": "Shares of Johnson & Johnson NYSE: JNJ are as cheap as they will get. The stock is down in premarket trading following the Q1 release, but there is a bottom in play and reality to face.", "url": "https://www.marketbeat.com/stock-ideas/johnson-and-johnson-is-as-cheap-as-its-going-to-get/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-16T09:15:49-04:00", "date_et": "2024-04-16"}
{"symbol": "JNJ", "publishedDate": "2024-04-16 09:15:49", "publisher": "MarketBeat", "title": "Johnson & Johnson is as Cheap as it's Going to Get", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-is-as-cheap-as-its-going-to-20240416.jpg", "site": "marketbeat.com", "text": "Shares of Johnson & Johnson NYSE: JNJ are as cheap as they will get. The stock is down in premarket trading following the Q1 release, but there is a bottom in play and reality to face.", "url": "https://www.marketbeat.com/stock-ideas/johnson-and-johnson-is-as-cheap-as-its-going-to-get/?utm_source=snapi", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-16T09:15:49-04:00", "date_et": "2024-04-16"}
{"symbol": "JNJ", "publishedDate": "2024-04-16 10:30:37", "publisher": "Investopedia", "title": "Johnson & Johnson Stock Slips After Mixed Q1 Earnings Report", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-stock-slips-after-mixed-q1-earnings-report-20240416.jpg", "site": "investopedia.com", "text": "Johnson & Johnson (JNJ) posted a mixed first-quarter earnings Tuesday, and raised its dividend while narrowing full-year guidance for 2024.", "url": "https://www.investopedia.com/johnson-and-johnson-stock-slips-after-mixed-q1-earnings-report-8634103", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-16T10:30:37-04:00", "date_et": "2024-04-16"}
{"symbol": "JNJ", "publishedDate": "2024-04-16 10:31:13", "publisher": "Zacks Investment Research", "title": "Johnson & Johnson (JNJ) Reports Q1 Earnings: What Key Metrics Have to Say", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-jnj-reports-q1-earnings-what-key-metrics-20240416.jpg", "site": "zacks.com", "text": "The headline numbers for Johnson & Johnson (JNJ) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.", "url": "https://www.zacks.com/stock/news/2255966/johnson-johnson-jnj-reports-q1-earnings-what-key-metrics-have-to-say?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|nfm-2255966", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-16T10:31:13-04:00", "date_et": "2024-04-16"}
{"symbol": "JNJ", "publishedDate": "2024-04-16 10:46:00", "publisher": "Business Wire", "title": "CORRECTING and REPLACING Johnson & Johnson Reports Q1 2024 Results", "image": "https://images.financialmodelingprep.com/news/correcting-and-replacing-johnson-johnson-reports-q1-2024-results-20240416.jpg", "site": "businesswire.com", "text": "NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--In the section titled \"Full-Year 2024 Guidance\", in the table, row titled \"Operational Sales2,5/ Mid-point\", the numbers for the April 2024 column should read: $88.7B – $89.1B / $88.9B (instead of: $88.7B – $89.1B / $88.0B). The updated release reads: JOHNSON & JOHNSON REPORTS Q1 2024 RESULTS Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2024. “Johnson & Johnson's solid first quarter performance reflects our sharpened f.", "url": "https://www.businesswire.com/news/home/20240416019157/en/CORRECTING-and-REPLACING-Johnson-Johnson-Reports-Q1-2024-Results/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-16T10:46:00-04:00", "date_et": "2024-04-16"}
{"symbol": "JNJ", "publishedDate": "2024-04-16 11:07:57", "publisher": "Proactive Investors", "title": "J&J's first quarter profits top estimates on strong cancer drug sales", "image": "https://images.financialmodelingprep.com/news/jjs-first-quarter-profits-top-estimates-on-strong-cancer-drug-20240416.jpg", "site": "proactiveinvestors.com", "text": "Johnson & Johnson (NYSE:JNJ) reported better-than-expected first quarter profits driven by strong sales of its cancer drugs, but shares of the pharma giant traded lower as revenue narrowly missed estimates. For Q1, the company reported that its adjusted earnings per share (EPS) increased by 12.4% to $2.71, topping estimates of $2.64.", "url": "https://www.proactiveinvestors.com/companies/news/1045425", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-16T11:07:57-04:00", "date_et": "2024-04-16"}
{"symbol": "JNJ", "publishedDate": "2024-04-16 11:07:57", "publisher": "Proactive Investors", "title": "J&J's first quarter profits top estimates on strong cancer drug sales", "image": "https://images.financialmodelingprep.com/news/jjs-first-quarter-profits-top-estimates-on-strong-cancer-20240416.jpg", "site": "proactiveinvestors.com", "text": "Johnson & Johnson (NYSE:JNJ) reported better-than-expected first quarter profits driven by strong sales of its cancer drugs, but shares of the pharma giant traded lower as revenue narrowly missed estimates. For Q1, the company reported that its adjusted earnings per share (EPS) increased by 12.4% to $2.71, topping estimates of $2.64.", "url": "https://www.proactiveinvestors.com/companies/news/1045425?SNAPI", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-16T11:07:57-04:00", "date_et": "2024-04-16"}
{"symbol": "JNJ", "publishedDate": "2024-04-16 11:30:16", "publisher": "Zacks Investment Research", "title": "Housing Numbers Shrink as Q1 Earnings Heat Up: BAC, JNJ, UNH", "image": "https://images.financialmodelingprep.com/news/housing-numbers-shrink-as-q1-earnings-heat-up-bac-20240416.jpg", "site": "zacks.com", "text": "Both Housing Starts and Building Permits missed expectations, while BofA, J&J and UnitedHealth all beat on earnings.", "url": "https://www.zacks.com/stock/news/2256163/housing-numbers-shrink-as-q1-earnings-heat-up-bac-jnj-unh?cid=CS-STOCKNEWSAPI-FT-ahead_of_wall_street-2256163", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-16T11:30:16-04:00", "date_et": "2024-04-16"}
{"symbol": "JNJ", "publishedDate": "2024-04-16 11:56:04", "publisher": "Zacks Investment Research", "title": "J&J (JNJ) Q1 Earnings Beat Estimates, Sales Miss, MedTech Soft", "image": "https://images.financialmodelingprep.com/news/jj-jnj-q1-earnings-beat-estimates-sales-miss-medtech-20240416.jpg", "site": "zacks.com", "text": "J&J (JNJ) beats estimates for first-quarter earnings but misses the same for sales. It tightens its sales and earnings growth expectations for 2024.", "url": "https://www.zacks.com/stock/news/2256185/j-j-jnj-q1-earnings-beat-estimates-sales-miss-medtech-soft?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_article-2256185", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-16T11:56:04-04:00", "date_et": "2024-04-16"}
{"symbol": "JNJ", "publishedDate": "2024-04-16 12:05:26", "publisher": "Zacks Investment Research", "title": "Building Permits Come in Lower Than Expected", "image": "https://images.financialmodelingprep.com/news/building-permits-come-in-lower-than-expected-20240416.jpg", "site": "zacks.com", "text": "Building Permits Come in Lower Than Expected.", "url": "https://www.zacks.com/stock/news/2256206/building-permits-come-in-lower-than-expected?cid=CS-STOCKNEWSAPI-FT-economic_highlights-2256206", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-16T12:05:26-04:00", "date_et": "2024-04-16"}
{"symbol": "JNJ", "publishedDate": "2024-04-16 12:19:01", "publisher": "Seeking Alpha", "title": "Johnson & Johnson (JNJ) Q1 2024 Earnings Call Transcript", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-jnj-q1-2024-earnings-call-transcript-20240416.jpg", "site": "seekingalpha.com", "text": "Johnson & Johnson (NYSE:JNJ ) Q1 2024 Earnings Conference Call April 16, 2024 8:30 AM ET Company Participants Jessica Moore - VP, IR Joaquin Duato - Chairman & CEO Joseph J. Wolk - EVP & CFO Jennifer L.", "url": "https://seekingalpha.com/article/4684056-johnson-and-johnson-jnj-q1-2024-earnings-call-transcript", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-16T12:19:01-04:00", "date_et": "2024-04-16"}
{"symbol": "JNJ", "publishedDate": "2024-04-16 13:07:41", "publisher": "PYMNTS", "title": "Johnson & Johnson Amplifies MedTech Profile in Q1 Earnings", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-amplifies-medtech-profile-in-q1-earnings-20240416.jpg", "site": "pymnts.com", "text": "Johnson & Johnson (J&J) has emphasized the pivotal role of medical technology (MedTech) in advancing healthcare. During a Tuesday (April 16) call with analysts to discuss the first quarter (Q1) and full-year 2023 financial results, the pharmaceutical giant underscored its commitment to bolstering its reputation as an “innovation powerhouse.", "url": "https://www.pymnts.com/earnings/2024/johnson-johnson-amplifies-medtech-profile-in-q1-earnings/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-16T13:07:41-04:00", "date_et": "2024-04-16"}
{"symbol": "JNJ", "publishedDate": "2024-04-16 13:07:41", "publisher": "PYMNTS", "title": "Johnson & Johnson Amplifies MedTech Profile in Q1 Earnings", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-amplifies-medtech-profile-in-q1-earnings-20240416.jpg", "site": "pymnts.com", "text": "Johnson & Johnson (J&J) has emphasized the pivotal role of medical technology (MedTech) in advancing healthcare. During a Tuesday (April 16) call with analysts to discuss the first quarter (Q1) and full-year 2023 financial results, the pharmaceutical giant underscored its commitment to bolstering its reputation as an “innovation powerhouse.", "url": "https://www.pymnts.com/earnings/2024/johnson-johnson-amplifies-medtech-profile-in-q1-earnings/?utm_source=snapi", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-16T13:07:41-04:00", "date_et": "2024-04-16"}
{"symbol": "JNJ", "publishedDate": "2024-04-16 13:17:12", "publisher": "Seeking Alpha", "title": "Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data", "image": "https://images.financialmodelingprep.com/news/intracellular-more-upside-possible-even-after-positive-mdd-treatment-20240416.jpg", "site": "seekingalpha.com", "text": "Intra-Cellular Therapies, Inc. achieved positive results from Study 501, using lumateperone as an adjunctive therapy for the treatment of patients with MDD; Both primary and secondary endpoints achieved with statistical significance.", "url": "https://seekingalpha.com/article/4684055-intra-cellular-more-upside-possible-even-after-positive-mdd-treatment-data", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-16T13:17:12-04:00", "date_et": "2024-04-16"}
{"symbol": "JNJ", "publishedDate": "2024-04-16 17:45:00", "publisher": "The Motley Fool", "title": "Why Johnson & Johnson Stock Got Tossed by the Market Today", "image": "https://images.financialmodelingprep.com/news/why-johnson-johnson-stock-got-tossed-by-the-market-20240416.jpg", "site": "fool.com", "text": "The healthcare titan unveiled its first set of quarterly results for 2024. It missed slightly on the top line but beat on profitability.", "url": "https://www.fool.com/investing/2024/04/16/why-johnson-johnson-stock-got-tossed-by-the-market/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-16T17:45:00-04:00", "date_et": "2024-04-16"}
{"symbol": "JNJ", "publishedDate": "2024-04-17 08:58:00", "publisher": "InvestorPlace", "title": "Put $10,000 in These 3 Dividend Stocks by 2025", "image": "https://images.financialmodelingprep.com/news/put-10000-in-these-3-dividend-stocks-by-2025-20240417.jpg", "site": "investorplace.com", "text": "While eagerly awaiting a Fed rate cut, we were surprised with a hotter-than-expected inflation report. This means the rate cuts could be delayed, and we might have to wait a few more months before an improvement in consumer spending.", "url": "https://investorplace.com/2024/04/put-10000-in-these-3-dividend-stocks-by-2025/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-17T08:58:00-04:00", "date_et": "2024-04-17"}
{"symbol": "JNJ", "publishedDate": "2024-04-17 09:35:07", "publisher": "24/7 Wall Street", "title": "Want $2000 In Passive Income? Invest $1000 Into These Dividend Stocks", "image": "https://images.financialmodelingprep.com/news/want-2000-in-passive-income-invest-1000-into-these-20240417.jpg", "site": "247wallst.com", "text": "Naturally, one should monitor their portfolio on a regular basis in case there are any news events or market circumstances that can affect a stock price or its dividend adversely.", "url": "https://247wallst.com/investing/2024/04/17/want-2000-in-passive-income-invest-1000-into-these-dividend-stocks/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-17T09:35:07-04:00", "date_et": "2024-04-17"}
{"symbol": "JNJ", "publishedDate": "2024-04-17 11:00:19", "publisher": "Zacks Investment Research", "title": "JNJ Beats Q1 Earnings Estimates, Misses on Sales: ETFs in Focus", "image": "https://images.financialmodelingprep.com/news/jnj-beats-q1-earnings-estimates-misses-on-sales-etfs-20240417.jpg", "site": "zacks.com", "text": "Johnson & Johnson (JNJ) continued with its long streak of earnings beat but lagged revenue estimates.", "url": "https://www.zacks.com/stock/news/2256952/jnj-beats-q1-earnings-estimates-misses-on-sales-etfs-in-focus?cid=CS-STOCKNEWSAPI-FT-etf_news_and_commentary-2256952", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-17T11:00:19-04:00", "date_et": "2024-04-17"}
{"symbol": "JNJ", "publishedDate": "2024-04-18 07:28:39", "publisher": "Seeking Alpha", "title": "Johnson & Johnson: Buy This Bargain Before It's Gone", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-buy-this-bargain-before-its-gone-20240418.jpg", "site": "seekingalpha.com", "text": "On April 16, Johnson & Johnson released financial results for the first three months of 2024, which were within my expectations. Tecvayli sales were $133 million in the first quarter of 2024, up 111% year over year. Despite increased competition in the global autoimmune disease therapeutics market, the sales growth rate of most of its blockbusters has pleasantly surprised me.", "url": "https://seekingalpha.com/article/4684406-johnson-johnson-earnings-buy-this-bargain-before-it-is-gone", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-18T07:28:39-04:00", "date_et": "2024-04-18"}
{"symbol": "JNJ", "publishedDate": "2024-04-18 10:23:15", "publisher": "InvestorPlace", "title": "Want to Double Your Tax Refund in 2024? 7 Stocks to Buy Now.", "image": "https://images.financialmodelingprep.com/news/want-to-double-your-tax-refund-in-2024-7-20240418.jpg", "site": "investorplace.com", "text": "Tax refunds are landing in bank accounts and mailboxes across America, giving people some extra money to play with. As of the federal income tax deadline of April 15, the Internal Revenue Service (IRS) has issued $201 billion worth of tax refunds.", "url": "https://investorplace.com/2024/04/want-to-double-your-tax-refund-in-2024-7-stocks-to-buy-now/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-18T10:23:15-04:00", "date_et": "2024-04-18"}
{"symbol": "JNJ", "publishedDate": "2024-04-18 12:08:11", "publisher": "InvestorPlace", "title": "Recession-Proof Riches: 3 Stocks That Thrive in Any Economy", "image": "https://images.financialmodelingprep.com/news/recessionproof-riches-3-stocks-that-thrive-in-any-economy-20240418.jpg", "site": "investorplace.com", "text": "Finding reliable assets is crucial in the current unstable environment. Even amid economic uncertainty, certain equities hold their value and offer steady returns.", "url": "https://investorplace.com/2024/04/recession-proof-riches-3-stocks-that-thrive-in-any-economy/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-18T12:08:11-04:00", "date_et": "2024-04-18"}
{"symbol": "JNJ", "publishedDate": "2024-04-18 17:23:38", "publisher": "Reuters", "title": "J&J wins trial over Florida woman who claimed its baby powder caused her cancer", "image": "https://images.financialmodelingprep.com/news/jj-wins-trial-over-florida-woman-who-claimed-its-20240418.jpg", "site": "reuters.com", "text": "A Florida jury on Thursday concluded that Johnson & Johnson's baby powder talc product did not cause the ovarian cancer of a Florida woman who died in 2019.", "url": "https://www.reuters.com/legal/jj-wins-trial-over-florida-woman-who-claimed-its-baby-powder-caused-her-cancer-2024-04-18/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-18T17:23:38-04:00", "date_et": "2024-04-18"}
{"symbol": "JNJ", "publishedDate": "2024-04-19 07:00:44", "publisher": "Forbes", "title": "What's Next For Johnson & Johnson Stock After Beating Q1 Earnings?", "image": "https://images.financialmodelingprep.com/news/whats-next-for-johnson-johnson-stock-after-beating-q1-20240419.jpg", "site": "forbes.com", "text": "Johnson & Johnson (NYSE: JNJ) recently reported its Q1 results, with revenues marginally below but earnings exceeding our estimates. The company reported revenue of $21.4 billion and adjusted earnings of $2.71 per share, compared to our estimates of $21.5 billion and $2.68, respectively.", "url": "https://www.forbes.com/sites/greatspeculations/2024/04/19/whats-next-for-johnson--johnson-stock-after-beating-q1-earnings/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-19T07:00:44-04:00", "date_et": "2024-04-19"}
{"symbol": "JNJ", "publishedDate": "2024-04-19 07:59:48", "publisher": "Reuters", "title": "WHO says wider alert on contaminated J&J cough syrup 'likely'", "image": "https://images.financialmodelingprep.com/news/who-says-wider-alert-on-contaminated-jj-cough-syrup-20240419.jpg", "site": "reuters.com", "text": "The World Health Organization is likely to issue a wider warning about contaminated Johnson and Johnson-made children's cough syrup found in Nigeria last week, it said in an email.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/who-says-wider-alert-contaminated-jj-cough-syrup-likely-2024-04-19/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-19T07:59:48-04:00", "date_et": "2024-04-19"}
{"symbol": "JNJ", "publishedDate": "2024-04-19 20:50:00", "publisher": "Business Wire", "title": "Illinois Jury Awards $45 Million in Mesothelioma Case Against Johnson & Johnson, Kenvue, Inc.", "image": "https://images.financialmodelingprep.com/news/illinois-jury-awards-45-million-in-mesothelioma-case-against-20240419.jpg", "site": "businesswire.com", "text": "CHICAGO--(BUSINESS WIRE)--A jury in the Circuit Court of Cook County in Chicago found Johnson & Johnson (NYSE:JNJ) and two subsidiaries liable in the asbestos-related death of a mother and grandmother, and awarded her family $45 million in damages. The jury concluded that Theresa Garcia's lifelong use of talc-based Johnson's Baby Powder and other products was the cause of her mesothelioma, an always-fatal cancer of the lining of the lungs caused by exposure to asbestos. Laboratory testing h.", "url": "https://www.businesswire.com/news/home/20240419166582/en/Illinois-Jury-Awards-45-Million-in-Mesothelioma-Case-Against-Johnson-Johnson-Kenvue-Inc./", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-19T20:50:00-04:00", "date_et": "2024-04-19"}
{"symbol": "JNJ", "publishedDate": "2024-04-20 06:37:00", "publisher": "InvestorPlace", "title": "Investing for the Long-Term: 3 Stocks With Proven Track Records", "image": "https://images.financialmodelingprep.com/news/investing-for-the-longterm-3-stocks-with-proven-track-20240420.jpg", "site": "investorplace.com", "text": "With continued volatility in the stock market right now, it's no wonder investors are looking for stocks with proven track records to bolster their portfolios. While U.S. stocks opened strong on Monday after a concerning ending to the prior week, investors are still uneasy about the current state of the market.", "url": "https://investorplace.com/2024/04/investing-for-the-long-term-3-stocks-with-proven-track-records/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-20T06:37:00-04:00", "date_et": "2024-04-20"}
{"symbol": "JNJ", "publishedDate": "2024-04-20 07:00:00", "publisher": "Seeking Alpha", "title": "20 Years To $300k? Building A $10,000 Dividend Portfolio From Scratch", "image": "https://images.financialmodelingprep.com/news/20-years-to-300k-building-a-10000-dividend-portfolio-20240420.jpg", "site": "seekingalpha.com", "text": "Focusing on consistent dividend growth can lead to higher returns in lower-risk areas. The portfolio emphasizes companies with wide-moat business models, strong financials, and a commitment to shareholder returns. Blending higher-yielding dividend stocks with those offering growth potential creates a balanced approach suitable for most investors.", "url": "https://seekingalpha.com/article/4684804-20-years-to-300k-building-a-10000-dividend-portfolio-from-scratch", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-20T07:00:00-04:00", "date_et": "2024-04-20"}
{"symbol": "JNJ", "publishedDate": "2024-04-20 07:00:00", "publisher": "Seeking Alpha", "title": "10 High-Yield Dividend Aristocrats Perfect For An Uncertain Market", "image": "https://images.financialmodelingprep.com/news/10-highyield-dividend-aristocrats-perfect-for-an-uncertain-market-20240420.jpg", "site": "seekingalpha.com", "text": "Volatility in the stock market is normal and healthy, with average yearly gains of 22% in positive years and average peak intra-year declines of -14%. Dividend aristocrats, which have lower volatility than the overall market, can be a good investment during market downturns. The ten lowest-volatility aristocrats offer a 3.1% average yield, a 50-year dividend growth streak, and an A-credit rating. Since 2007, they have fallen 50% less than the S&P during bear markets.", "url": "https://seekingalpha.com/article/4684035-10-high-yield-dividend-aristocrats-perfect-for-uncertain-market", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-20T07:00:00-04:00", "date_et": "2024-04-20"}
{"symbol": "JNJ", "publishedDate": "2024-04-20 15:25:55", "publisher": "Forbes", "title": "Court Orders Johnson & Johnson And Kenvue To Pay $45 Million In Talcum Baby Powder Lawsuit", "image": "https://images.financialmodelingprep.com/news/court-orders-johnson-johnson-and-kenvue-to-pay-45-20240420.jpg", "site": "forbes.com", "text": "An Illinois court late Friday ordered pharmaceutical giant Johnson & Johnson and Kenvue to pay $45 million to a family that alleged the companies' talcum-based baby powder led to the death of a relative diagnosed with a fatal cancer linked to asbestos exposure, the company's latest legal issue involving talc products.", "url": "https://www.forbes.com/sites/caileygleeson/2024/04/20/court-orders-johnson--johnson-and-kenvue-to-pay-45-million-in-talcum-baby-powder-lawsuit/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-20T15:25:55-04:00", "date_et": "2024-04-20"}
{"symbol": "JNJ", "publishedDate": "2024-04-22 08:00:00", "publisher": "Seeking Alpha", "title": "Dividend Income Summary: Lanny's March 2024 Summary", "image": "https://images.financialmodelingprep.com/news/dividend-income-summary-lannys-march-2024-summary-20240422.jpg", "site": "seekingalpha.com", "text": "2023 was up 24%. 3 months down in 2024 and the S&P 500 is already up 6%, down from the plus 10% they were at.", "url": "https://seekingalpha.com/article/4685054-dividend-income-summary-lannys-march-2024-summary", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-22T08:00:00-04:00", "date_et": "2024-04-22"}
{"symbol": "JNJ", "publishedDate": "2024-04-22 08:00:00", "publisher": "InvestorPlace", "title": "5 Crash-Proof Stocks to Buy Immediately", "image": "https://images.financialmodelingprep.com/news/5-crashproof-stocks-to-buy-immediately-20240422.png", "site": "investorplace.com", "text": "In February, I recommended five one-month momentum plays to buy as Bitcoin ( BTC-USD ) prices surged. The world's largest cryptocurrency is a surprisingly good gauge of bubbly investor sentiment, and our writers at InvestorPlace.com had found several strong candidates to ride the market higher.", "url": "https://investorplace.com/2024/04/5-crash-proof-stocks-to-buy-immediately/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-22T08:00:00-04:00", "date_et": "2024-04-22"}
{"symbol": "JNJ", "publishedDate": "2024-04-22 10:05:38", "publisher": "Zacks Investment Research", "title": "Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-jnj-is-a-trending-stock-facts-to-20240422.jpg", "site": "zacks.com", "text": "Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.", "url": "https://www.zacks.com/stock/news/2259015/johnson-johnson-jnj-is-a-trending-stock-facts-to-know-before-betting-on-it?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|most_searched_stocks-2259015", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-22T10:05:38-04:00", "date_et": "2024-04-22"}
{"symbol": "JNJ", "publishedDate": "2024-04-22 13:04:38", "publisher": "Seeking Alpha", "title": "Johnson & Johnson: Legal Woes Are Detrimental But Not Fatal", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-legal-woes-are-detrimental-but-not-fatal-20240422.jpg", "site": "seekingalpha.com", "text": "Johnson & Johnson stock has continued to underperform the healthcare sector, worrying JNJ investors. JNJ's potentially massive talc-related legal liabilities will likely affect buying sentiment. However, it's easy to forget that JNJ is a fundamentally strong business with robust free cash flow profitability.", "url": "https://seekingalpha.com/article/4685107-johnson-and-johnson-legal-woes-are-detrimental-but-not-fatal", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-22T13:04:38-04:00", "date_et": "2024-04-22"}
{"symbol": "JNJ", "publishedDate": "2024-04-22 16:30:00", "publisher": "Business Wire", "title": "Johnson & Johnson to Participate in the Bernstein's 40th Annual Strategic Decisions Conference (SDC)", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-to-participate-in-the-bernsteins-40th-annual-20240422.jpg", "site": "businesswire.com", "text": "NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the Bernstein's 40th Annual Strategic Decisions Conference (SDC) on Wednesday, May 29th, at the New York Hilton Midtown, New York, NY. Joaquin Duato, Chairman and Chief Executive Officer will represent the Company in a session scheduled at 1:30 pm (Eastern Time). This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.inves.", "url": "https://www.businesswire.com/news/home/20240422476745/en/Johnson-Johnson-to-Participate-in-the-Bernstein%E2%80%99s-40th-Annual-Strategic-Decisions-Conference-SDC/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-22T16:30:00-04:00", "date_et": "2024-04-22"}
{"symbol": "JNJ", "publishedDate": "2024-04-23 09:46:05", "publisher": "Zacks Investment Research", "title": "4 Stocks to Watch on Their Recent Dividend Hikes", "image": "https://images.financialmodelingprep.com/news/4-stocks-to-watch-on-their-recent-dividend-hikes-20240423.jpg", "site": "zacks.com", "text": "Stocks like KB Home (KBH), Interactive Brokers Group, Inc. (IBKR), QUALCOMM Incorporated (QCOM) and Johnson & Johnson (JNJ) recently hiked dividends.", "url": "https://www.zacks.com/stock/news/2260121/4-stocks-to-watch-on-their-recent-dividend-hikes?cid=CS-STOCKNEWSAPI-FT-analyst_blog|investment_ideas-2260121", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-23T09:46:05-04:00", "date_et": "2024-04-23"}
{"symbol": "JNJ", "publishedDate": "2024-04-23 16:30:00", "publisher": "InvestorPlace", "title": "Warning! These 3 Blue-Chip Stocks Will Have You Seeing Red", "image": "https://images.financialmodelingprep.com/news/warning-these-3-bluechip-stocks-will-have-you-seeing-red-20240423.jpg", "site": "investorplace.com", "text": "Not all stocks have succeeded in the bull market that began about 18 months ago. In the current market, a rising tide has not lifted all boats.", "url": "https://investorplace.com/2024/04/warning-these-3-blue-chip-stocks-will-have-you-seeing-red/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-23T16:30:00-04:00", "date_et": "2024-04-23"}
{"symbol": "JNJ", "publishedDate": "2024-04-24 05:25:00", "publisher": "The Motley Fool", "title": "Got $5,000? Here Are 3 Undervalued Stocks to Buy and Hold Forever", "image": "https://images.financialmodelingprep.com/news/got-5000-here-are-3-undervalued-stocks-to-buy-20240424.jpg", "site": "fool.com", "text": "Altria offers an outsized dividend with little risk of a cut. Johnson & Johnson isn't flashy, but it's a bargain you shouldn't pass up.", "url": "https://www.fool.com/investing/2024/04/24/got-5000-here-are-3-undervalued-stocks-to-buy-and/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-24T05:25:00-04:00", "date_et": "2024-04-24"}
{"symbol": "JNJ", "publishedDate": "2024-04-24 07:25:00", "publisher": "InvestorPlace", "title": "The Top 7 Dividend Stocks to Buy in 2024 to Build Lasting Wealth", "image": "https://images.financialmodelingprep.com/news/the-top-7-dividend-stocks-to-buy-in-2024-20240424.jpg", "site": "investorplace.com", "text": "In the changing environment of 2024, astute investors have a plethora of options to strengthen their financial portfolios strategically by purchasing dividend stocks. These prospects result from industry titans' forward-thinking initiatives and solid performance.", "url": "https://investorplace.com/2024/04/the-top-7-dividend-stocks-to-buy-in-2024-to-build-lasting-wealth/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-24T07:25:00-04:00", "date_et": "2024-04-24"}
{"symbol": "JNJ", "publishedDate": "2024-04-24 14:35:00", "publisher": "Business Wire", "title": "PBIRx Growth Fueled by Johnson & Johnson ERISA Lawsuit", "image": "https://images.financialmodelingprep.com/news/pbirx-growth-fueled-by-johnson-johnson-erisa-lawsuit-20240424.jpg", "site": "businesswire.com", "text": "MILFORD, Conn.--(BUSINESS WIRE)-- #SOC2--PBIRx, a pharmacy benefits consulting and auditing firm, sees growth from concerns over alleged fiduciary breach lawsuit against Johnson & Johnson.", "url": "https://www.businesswire.com/news/home/20240424130432/en/PBIRx-Growth-Fueled-by-Johnson-Johnson-ERISA-Lawsuit/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-24T14:35:00-04:00", "date_et": "2024-04-24"}
{"symbol": "JNJ", "publishedDate": "2024-04-25 06:50:00", "publisher": "InvestorPlace", "title": "7 blue chip stocks to Buy on the Dip: April 2024", "image": "https://images.financialmodelingprep.com/news/7-blue-chip-stocks-to-buy-on-the-dip-20240425.png", "site": "investorplace.com", "text": "Recent market volatility may have many market participants buying major tech stocks on the dip, but the genuine opportunity may lie with blue chip stocks to buy on the dip. Blue-chips can be a great cornerstone for your portfolio.", "url": "https://investorplace.com/2024/04/7-blue-chip-stocks-to-buy-on-the-dip-april-2024/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-25T06:50:00-04:00", "date_et": "2024-04-25"}
{"symbol": "JNJ", "publishedDate": "2024-04-25 13:35:00", "publisher": "Seeking Alpha", "title": "Bert's March Dividend Income Summary", "image": "https://images.financialmodelingprep.com/news/berts-march-dividend-income-summary-20240425.jpg", "site": "seekingalpha.com", "text": "March is one of the lower months for SCHD for dividend payments. Realty Income has been one of my top stock buys in 2024.", "url": "https://seekingalpha.com/article/4686232-berts-march-dividend-income-summary", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-25T13:35:00-04:00", "date_et": "2024-04-25"}
{"symbol": "JNJ", "publishedDate": "2024-04-26 06:00:00", "publisher": "InvestorPlace", "title": "How Much Will $10k Invested in These Dividend Aristocrats Grow to by 2025?", "image": "https://images.financialmodelingprep.com/news/how-much-will-10k-invested-in-these-dividend-aristocrats-20240426.jpg", "site": "investorplace.com", "text": "Investors don't have to look far to find justification for investing in dividend aristocrats. Generally speaking, dividends are an excellent way to secure stable returns and compound one's wealth.", "url": "https://investorplace.com/2024/04/how-much-will-10k-invested-in-these-dividend-aristocrats-grow-to-by-2025/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-26T06:00:00-04:00", "date_et": "2024-04-26"}
{"symbol": "JNJ", "publishedDate": "2024-04-26 09:16:11", "publisher": "Zacks Investment Research", "title": "5 Stocks in Focus on Their Recent Dividend Hike", "image": "https://images.financialmodelingprep.com/news/5-stocks-in-focus-on-their-recent-dividend-hike-20240426.jpg", "site": "zacks.com", "text": "Five stocks to focus with recent dividend hike are: JNJ, TRV, SON, KBH, SPFI.", "url": "https://www.zacks.com/stock/news/2263132/5-stocks-in-focus-on-their-recent-dividend-hike?cid=CS-STOCKNEWSAPI-FT-analyst_blog|investment_ideas-2263132", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-26T09:16:11-04:00", "date_et": "2024-04-26"}
{"symbol": "JNJ", "publishedDate": "2024-04-26 12:45:25", "publisher": "Zacks Investment Research", "title": "Are You Looking for a High-Growth Dividend Stock?", "image": "https://images.financialmodelingprep.com/news/are-you-looking-for-a-highgrowth-dividend-stock-20240426.jpg", "site": "zacks.com", "text": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?", "url": "https://www.zacks.com/stock/news/2263489/are-you-looking-for-a-high-growth-dividend-stock?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_5-2263489", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-26T12:45:25-04:00", "date_et": "2024-04-26"}
{"symbol": "JNJ", "publishedDate": "2024-04-27 06:00:00", "publisher": "InvestorPlace", "title": "Generational Wealth Builders: 3 Stocks to Own for Decades of Gains", "image": "https://images.financialmodelingprep.com/news/generational-wealth-builders-3-stocks-to-own-for-decades-20240427.jpg", "site": "investorplace.com", "text": "Looking for long-term stocks to buy for decades of gains requires a strategy focusing on stable, established companies with proven track records. The key to selecting long-term stocks to buy to build generational wealth is identifying companies with strong fundamentals, competitive advantages, and financial stability over time.", "url": "https://investorplace.com/2024/04/three-stocks-to-own-for-decades-of-gains/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-27T06:00:00-04:00", "date_et": "2024-04-27"}
{"symbol": "JNJ", "publishedDate": "2024-04-27 07:45:00", "publisher": "The Motley Fool", "title": "Johnson & Johnson Stock: Buy, Sell, or Hold?", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-stock-buy-sell-or-hold-20240427.jpg", "site": "fool.com", "text": "Johnson & Johnson's business generated modest single-digit growth last quarter. The drugmaker announced it will be raising its dividend for a 62nd consecutive year.", "url": "https://www.fool.com/investing/2024/04/27/johnson-johnson-stock-buy-sell-or-hold/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-27T07:45:00-04:00", "date_et": "2024-04-27"}
{"symbol": "JNJ", "publishedDate": "2024-04-28 04:20:00", "publisher": "The Motley Fool", "title": "Better Dividend Stock: AbbVie or Johnson & Johnson?", "image": "https://images.financialmodelingprep.com/news/better-dividend-stock-abbvie-or-johnson-johnson-20240428.jpg", "site": "fool.com", "text": "AbbVie and Johnson & Johnson have excellent dividend track records and solid businesses. However, one of these healthcare giants has a slight edge over the other.", "url": "https://www.fool.com/investing/2024/04/28/better-dividend-stock-abbvie-or-johnson-johnson/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-28T04:20:00-04:00", "date_et": "2024-04-28"}
{"symbol": "JNJ", "publishedDate": "2024-04-28 08:45:00", "publisher": "The Motley Fool", "title": "2 Top Growth Stocks to Buy Right Now and Hold Forever", "image": "https://images.financialmodelingprep.com/news/2-top-growth-stocks-to-buy-right-now-and-20240428.jpg", "site": "fool.com", "text": "The healthcare industry tends to do well in all types of economies. Vertex just garnered a new blockbuster approval, and more could be around the corner.", "url": "https://www.fool.com/investing/2024/04/28/2-top-growth-stocks-to-buy-now-and-hold-forever/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-28T08:45:00-04:00", "date_et": "2024-04-28"}
{"symbol": "JNJ", "publishedDate": "2024-04-29 10:03:13", "publisher": "InvestorPlace", "title": "7 Retirement Stocks to Buy at a 52-Week Low in April", "image": "https://images.financialmodelingprep.com/news/7-retirement-stocks-to-buy-at-a-52week-low-20240429.png", "site": "investorplace.com", "text": "One of the best ways to keep your portfolio safe while generating consistent income is in safe, dividend-paying retirement stocks at 52-week lows. It's even better if you're buying into a reputable company that's paid out dividends for years, and is on sale.", "url": "https://investorplace.com/2024/04/7-retirement-stocks-to-buy-at-a-52-week-low-in-april/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-29T10:03:13-04:00", "date_et": "2024-04-29"}
{"symbol": "JNJ", "publishedDate": "2024-04-29 10:23:00", "publisher": "The Motley Fool", "title": "Johnson & Johnson Is a King of Dividend Safety", "image": "https://images.financialmodelingprep.com/news/johnson-johnson-is-a-king-of-dividend-safety-20240429.jpg", "site": "fool.com", "text": "Johnson & Johnson has a higher credit rating than the U.S. Federal Government. The healthcare giant is in the elite class of Dividend Kings.", "url": "https://www.fool.com/investing/2024/04/29/johnson-johnson-is-a-king-of-dividend-safety/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-29T10:23:00-04:00", "date_et": "2024-04-29"}
{"symbol": "JNJ", "publishedDate": "2024-04-29 17:07:42", "publisher": "InvestorPlace", "title": "Cutting Edge Picks: 3 Med Tech Stocks With Room to Run", "image": "https://images.financialmodelingprep.com/news/cutting-edge-picks-3-med-tech-stocks-with-room-20240429.png", "site": "investorplace.com", "text": "Undoubtedly, investors seem to have a new appetite for next-level revenue growth. Generative AI, GLP-1 weight-loss drugs and other breakthrough innovations (I'm not sure if the metaverse qualifies right now) seek to expand in some pretty massive markets.", "url": "https://investorplace.com/2024/04/cutting-edge-picks-3-med-tech-stocks-with-room-to-run/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-29T17:07:42-04:00", "date_et": "2024-04-29"}
{"symbol": "JNJ", "publishedDate": "2024-04-29 17:57:42", "publisher": "Reuters", "title": "J&J, Bristol Myers lose challenges to US drug price negotiation program", "image": "https://images.financialmodelingprep.com/news/jj-bristol-myers-lose-challenges-to-us-drug-price-20240429.jpg", "site": "reuters.com", "text": "A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.", "url": "https://www.reuters.com/legal/jj-bristol-myers-lose-challenges-us-drug-price-negotiation-program-2024-04-29/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-29T17:57:42-04:00", "date_et": "2024-04-29"}
{"symbol": "JNJ", "publishedDate": "2024-04-29 18:22:04", "publisher": "CNBC", "title": "Judge rejects J&J, Bristol Myers Squibb challenges to Medicare drug price negotiations", "image": "https://images.financialmodelingprep.com/news/judge-rejects-jj-bristol-myers-squibb-challenges-to-medicare-20240429.jpeg", "site": "cnbc.com", "text": "The decision is another win for the Biden administration in a bitter legal fight with several drugmakers over the constitutionality of the price talks.", "url": "https://www.cnbc.com/2024/04/29/jj-bristol-myers-squibb-lose-medicare-drug-price-talks-challenges.html", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-29T18:22:04-04:00", "date_et": "2024-04-29"}
{"symbol": "JNJ", "publishedDate": "2024-04-30 07:17:00", "publisher": "InvestorPlace", "title": "Slump Survivors: 3 Stocks That Will Outlast the S&P 500 Downturn", "image": "https://images.financialmodelingprep.com/news/slump-survivors-3-stocks-that-will-outlast-the-sp-20240430.png", "site": "investorplace.com", "text": "If you're searching for stocks to outperform the S&P 500, look no further. Some stocks are more solid than others against market downturns and macro-economic uncertainty and have high chances of beating the S&P 500 index.", "url": "https://investorplace.com/2024/04/slump-survivors-3-stocks-that-will-outlast-the-sp-500-downturn/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-30T07:17:00-04:00", "date_et": "2024-04-30"}
{"symbol": "JNJ", "publishedDate": "2024-04-30 07:31:39", "publisher": "MarketBeat", "title": "3 Stocks Mega Investors Are Buying", "image": "https://images.financialmodelingprep.com/news/3-stocks-mega-investors-are-buying-20240430.jpg", "site": "marketbeat.com", "text": "When the biggest names on Wall Street make an investment decision, the world listens. As the first quarter of 2024 comes to a close, SEC 13-F filings are coming in hot, showing investors where some of the biggest fund managers are finding investing opportunities despite market indexes hovering near all-time highs.", "url": "https://www.marketbeat.com/stock-ideas/3-stocks-mega-investors-are-buying/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-30T07:31:39-04:00", "date_et": "2024-04-30"}
{"symbol": "JNJ", "publishedDate": "2024-04-30 09:42:51", "publisher": "InvestorPlace", "title": "Stock Market Crash Warning: Don't Get Caught Holding These 3 Healthcare Stocks", "image": "https://images.financialmodelingprep.com/news/stock-market-crash-warning-dont-get-caught-holding-these-20240430.png", "site": "investorplace.com", "text": "The healthcare industry has experienced unprecedented growth in recent years due to the global pandemic. However, as COVID-19 began to ease, the immense growth of the healthcare industry is expected to slow down.", "url": "https://investorplace.com/2024/04/stock-market-crash-warning-dont-get-caught-holding-these-3-healthcare-stocks/", "ticker": "JNJ", "event_date": "2024-04-16", "window_start": "2024-04-02", "window_end": "2024-04-30", "publishedDateET": "2024-04-30T09:42:51-04:00", "date_et": "2024-04-30"}
